EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Is There a Diagnostic Miracle on the Horizon? Emerging Biomarkers in MASLD

Klaudyna Iwaszko-Sochal iD, Beata Kasztelan-Szczerbińska iD, Halina Cichoż-Lach

Journal of Clinical Medicine · 30.08.2025 · 14 (17) · 6148

DOI: 10.3390/jcm14176148 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 30.08.2025. Verfasst von Klaudyna Iwaszko-Sochal und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology with Endoscopy Unit, Medical University of Lublin, Jaczewskiego 8, 20-954 Lublin, Poland. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The incidence and prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) are increasing, and, currently, the disease affects approximately 30% of the global population. Therefore, there is a growing need for widely available, patient-friendly, and reliable diagnostic tools. Our review is focused on the presentation and discussion of emerging biomarkers for evaluation and non-invasive detection of liver fibrosis in patients with MASLD, including glycation markers (AGEs/sRAGE), lipid mediators (eicosanoids), fetuin-A, collagen turnover markers (PRO-C3, ADAPT), and omic-based technologies. As reported recently, some of these parameters revealed high diagnostic accuracy in clinical trials, so they may be incorporated as key diagnostic tools in the future MASLD approach. Employment of such biomarkers may enable correct and quick identification of MASLD and/or MASH patients, as well as better monitoring of their treatment response. The development of precision medicine, driven by multiomics and individualized profiling, promises a rearrangement from the traditional “one size fits all” to tailoring targeted care, as environmental factors may have an even more relevant impact on MASLD pathogenesis in comparison with genetic predisposition. Nevertheless, to enable their widespread clinical use, novel biomarkers require further rigorous validation and standardized implementation in healthcare settings.

Schlagwörter

Stichwörter der Autor:innen

ADAPTAGEsMASLDPRO-C3biomarkerseicosanoidsfetuin-Aomicsprecision medicinesRAGE

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology with Endoscopy Unit, Medical University of Lublin, Jaczewskiego 8, 20-954 Lublin, Poland.

ORCID-Profile: Klaudyna Iwaszko-Sochal, Beata Kasztelan-Szczerbińska

Zitieren

APA

Iwaszko-Sochal, K., Kasztelan-Szczerbińska, B., & Cichoż-Lach, H. (2025). Is There a Diagnostic Miracle on the Horizon? Emerging Biomarkers in MASLD. Journal of Clinical Medicine, 14(17), 6148. https://doi.org/10.3390/jcm14176148

Vancouver

Iwaszko-Sochal K, Kasztelan-Szczerbińska B, Cichoż-Lach H. Is There a Diagnostic Miracle on the Horizon? Emerging Biomarkers in MASLD. Journal of Clinical Medicine. 2025;14(17):6148. doi:10.3390/jcm14176148

BibTeX
@article{IwaszkoSochal2025,
  author = {Iwaszko-Sochal, Klaudyna and Kasztelan-Szczerbińska, Beata and Cichoż-Lach, Halina},
  title = {Is There a Diagnostic Miracle on the Horizon? Emerging Biomarkers in MASLD},
  journal = {Journal of Clinical Medicine},
  year = {2025},
  volume = {14},
  number = {17},
  pages = {6148},
  doi = {10.3390/jcm14176148}
}
Kostenlos starten →